公开(公告)号：NZ237899A

公开(公告)日：1997-03-24

申请号：NZ23789991

申请日：1991-04-22

Applicant: VIVUS INC SUBSTITUTED FOR ALZA

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K9/02 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12 ,  A61K45/08 ,  A61F2/26

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：NO963916L

公开(公告)日：1996-11-21

申请号：NO963916

申请日：1996-09-19

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61B5/00 ,  A61B5/055 ,  A61B5/103 ,  A61B5/11 ,  A61B5/20 ,  A61B8/06 ,  A61F5/41 ,  A61K9/00 ,  A61K49/00 ,  A61M31/00 ,  A61B19/00

Abstract: A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonography, NMR, angiography, or the like. Kits for conducting the diagnostic method are provided as well, as are methods of treatment based on the diagnostic conclusion.

公开(公告)号：CA2215307A1

公开(公告)日：1996-09-19

申请号：CA2215307

申请日：1996-03-07

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61K38/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/445 ,  A61K31/48 ,  A61K31/505 ,  A61K31/54 ,  A61K31/557 ,  A61K33/00 ,  A61K45/00 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00

Abstract: A method is provided for preventing erectile dysfunction, particularly vasculogenic impotence, in a male individual. The method involves periodic administration of a vasoactive agent throughout a 24-hour period. The agent and dosage regimen are selected such that regularly increased blood flow to the penis is achieved, in turn preventing arterial occlusion and vascular deterioration of the muscular fibers of the vessels and collagen fibers of the cavernosal tissue.

公开(公告)号：CA2186382A1

公开(公告)日：1995-10-05

申请号：CA2186382

申请日：1995-03-20

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61B5/00 ,  A61B5/055 ,  A61B5/103 ,  A61B5/11 ,  A61B5/20 ,  A61B8/06 ,  A61F5/41 ,  A61K9/00 ,  A61K49/00 ,  A61M31/00 ,  A61B5/02 ,  A61B8/00

Abstract: A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonography, NMR, angiography, or the like. Kits for conducting the diagnostic method are provided as well, as are methods of treatment based on the diagnostic conclusion. The kits for diagnosing erectile dysfunction comprise a vasodilating agent (4) effective to induce erection of the penis, a drug delivery means (1, 11, or 49) for administering the vasodilating agent transurethrally, a container (15 or 55) for housing the agent and drug delivery means, and written instructions for using the agent and the drug delivery means.

公开(公告)号：AU7856391A

公开(公告)日：1991-11-11

申请号：AU7856391

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61K9/02 ,  A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K47/10 ,  A61K9/22

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.